

=> d his

(FILE 'HOME' ENTERED AT 14:48:07 ON 02 NOV 2004)

FILE 'CAPLUS' ENTERED AT 14:48:16 ON 02 NOV 2004

L1 0 S WO03057217/PN
L2 1 S WO2003057217/PN
SELECT L2 1 RN
L3 16405 S E1-E7

FILE 'REGISTRY' ENTERED AT 14:49:33 ON 02 NOV 2004

L4 1 S 122111-03-9/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:49:53 ON 02 NOV 2004

L5 1 S 152044-54-7/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY
L6 0 S WO9902514/PN

FILE 'CAPLUS' ENTERED AT 14:51:49 ON 02 NOV 2004

L7 0 S L6
L8 1 S WO9902514/PN
SELECT L8 1 RN
L9 35596 S E8-E82

FILE 'REGISTRY' ENTERED AT 14:59:11 ON 02 NOV 2004

L10 1 S 219989-84-1/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 15:00:36 ON 02 NOV 2004

L11 1 S 208521-14-6/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:02:20 ON 02 NOV 2004

L12 59 S E24-E75
L13 40 S L12 AND (CANCER# OR TUMOR# OR NEOPLAS? OR PROLIFERA?)

=>

=> s e24-e75

3 219989-70-5/BI
3 219989-71-6/BI
3 219989-72-7/BI
3 219989-73-8/BI
3 219989-74-9/BI
3 219989-75-0/BI
3 219989-76-1/BI
4 219989-77-2/BI
3 219989-79-4/BI
3 219989-80-7/BI
3 219989-81-8/BI
1 219989-82-9/BI
3 219989-83-0/BI
47 219989-84-1/BI
3 219989-85-2/BI
14 219989-87-4/BI
5 219989-88-5/BI
3 219989-89-6/BI
3 219989-90-9/BI
3 219989-91-0/BI
4 219989-92-1/BI
3 219989-93-2/BI
3 219989-94-3/BI
3 219989-95-4/BI
3 219989-96-5/BI
3 219989-97-6/BI
3 219989-98-7/BI
3 219989-99-8/BI
3 219990-00-8/BI
3 219990-01-9/BI
3 219990-02-0/BI
3 219990-03-1/BI
3 219990-04-2/BI
3 219990-05-3/BI
2 219990-06-4/BI
2 219990-07-5/BI
2 219990-08-6/BI
1 219990-09-7/BI
1 219990-10-0/BI
2 219990-11-1/BI
3 219990-12-2/BI
2 219990-13-3/BI
3 219990-14-4/BI
2 219990-15-5/BI
2 219990-16-6/BI
1 219990-18-8/BI
1 219990-21-3/BI
5 219990-23-5/BI
5 219990-25-7/BI
9 219990-27-9/BI
2 219990-29-1/BI
1 219990-32-6/BI

L12

59 (219989-70-5/BI OR 219989-71-6/BI OR 219989-72-7/BI OR 219989-73-8/BI OR 219989-74-9/BI OR 219989-75-0/BI OR 219989-76-1/BI OR 219989-77-2/BI OR 219989-79-4/BI OR 219989-80-7/BI OR 219989-81-8/BI OR 219989-82-9/BI OR 219989-83-0/BI OR 219989-84-1/BI OR 219989-85-2/BI OR 219989-87-4/BI OR 219989-88-5/BI OR 219989-89-6/BI OR 219989-90-9/BI OR 219989-91-0/BI OR 219989-92-1/BI OR 219989-93-2/BI OR 219989-94-3/BI OR 219989-95-4/BI OR 219989-96-5/BI OR 219989-97-6/BI OR 219989-98-7/BI OR 219989-99-8/BI OR 219990-00-8/BI OR 219990-01-9/BI OR 219990-02-0/BI OR 219990-03-1/BI OR 219990-04-2/BI OR 219990-05-3/BI OR 219990-06-4/BI OR 219990-07-5/BI OR 219990-08-6/BI OR 219990-09-7/BI OR 219990-10-0/BI OR 219990-11-1/BI OR 219990-12-2/BI OR 219990-13-3/BI OR 219990-14-4/BI OR 219990-15-5/BI OR 219990-16-6/BI OR 219990-18-8/BI OR 219990-21-3/BI OR 219990-23-5/BI OR 219990-25-7/BI OR 219990-27-9/BI OR 219990-29-1/BI OR 219990-32-6/BI)

=> s l12 and (cancer# or tumor# or neoplas? or prolifera?)

236481 CANCER#

361213 TUMOR#

387039 NEOPLAS?

203737 PROLIFERA?

L13 40 L12 AND (CANCER# OR TUMOR# OR NEOPLAS? OR PROLIFERA?)

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 219989-84-1 REGISTRY

CN 17-Oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-
8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-
, (1S,3S,7S,10R,11S,12S,16R) - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Azaepothilone B

CN BMS 247550

CN BMS 247550-1

CN Ixabepilone

FS STEREOSEARCH

MF C27 H42 N2 O5 S

SR CA

LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, CASREACT, EMBASE,
IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROUSDDR, RTECS*,
TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

DT.CA Caplus document type: Journal; Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC
(Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES
(Uses)

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

47 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

47 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:77585 CAPLUS
DOCUMENT NUMBER: 138:137091
TITLE: Preparation of epothilone derivatives for therapeutic use as antitumor agents
INVENTOR(S): Ashley, Gary; Metcalf, Brian
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 38 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003023082	A1	20030130	US 2002-145405	20020513
PRIORITY APPLN. INFO.:			US 2001-291242P	P 20010515
			US 2001-309099P	P 20010731
OTHER SOURCE(S):	MARPAT 138:137091			

L13 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:946278 CAPLUS
DOCUMENT NUMBER: 138:24591
TITLE: Preparation of epothilone derivatives for therapeutic use as anti-**cancer** agents
INVENTOR(S): Regueiro-Ren, Alicia; Borzilleri, Robert M.; Vite, Gregory D.; Kim, Soong-Hoon
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098868	A1	20021212	WO 2002-US15397	20020514
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003087888	A1	20030508	US 2002-144879	20020514
US 6800653	B2	20041005		
EP 1392664	A1	20040303	EP 2002-736867	20020514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004532888	T2	20041028	JP 2003-501991	20020514
PRIORITY APPLN. INFO.:			US 2001-295499P	P 20010601
			WO 2002-US15397	W 20020514
OTHER SOURCE(S):	MARPAT 138:24591			
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L13 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:914017 CAPLUS
DOCUMENT NUMBER: 139:16894
TITLE: Pharmacological treatments for prostate **cancer**
AUTHOR(S): Walczak, Janet R.; Carducci, Michael A.
CORPORATE SOURCE: Johns Hopkins University, Department of Nursing,

SOURCE: Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins, School of Medicine, Baltimore, MD, USA
Expert Opinion on Investigational Drugs (2002), 11(12), 1737-1748
CODEN: EOIDER; ISSN: 1354-3784

PUBLISHER: Ashley Publications Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:716079 CAPLUS

DOCUMENT NUMBER: 137:242152

TITLE: Combination of epothilone analogs and chemotherapeutic agents for the treatment of **proliferative** diseases

INVENTOR(S): Lee, Francis Y. F.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072085	A1	20020919	WO 2002-US6746	20020305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003073677	A1	20030417	US 2002-91061	20020305
EE 200300440	A	20031215	EE 2003-440	20020305
EP 1383490	A1	20040128	EP 2002-717548	20020305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007961	A	20040420	BR 2002-7961	20020305
JP 2004529904	T2	20040930	JP 2002-571044	20020305
NO 2003004056	A	20031105	NO 2003-4056	20030912
US 2004214871	A1	20041028	US 2004-850072	20040520
PRIORITY APPLN. INFO.:				
			US 2001-275801P	P 20010314
			US 2001-316395P	P 20010831
			US 2002-91061	A3 20020305
			WO 2002-US6746	W 20020305
OTHER SOURCE(S): MARPAT 137:242152				
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

instant application

L13 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:657954 CAPLUS

DOCUMENT NUMBER: 137:195554

TITLE: Treatment of refractory **tumors** using epothilone derivatives

INVENTOR(S): Lee, Francis Y. F.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066038	A1	20020829	WO 2002-US4255	20020206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EE 200300396	A	20031215	EE 2003-396	20020206
EP 1385529	A1	20040204	EP 2002-714885	20020206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004522774	T2	20040729	JP 2002-565596	20020206
BR 2002007487	A	20040810	BR 2002-7487	20020206
US 2002165258	A1	20021107	US 2002-72123	20020208
US 6686380 <i>opp</i>	B2	20040203		
NO 2003003684	A	20031013	NO 2003-3684	20030819
PRIORITY APPLN. INFO.:			US 2001-269836P	P 20010220
			WO 2002-US4255	W 20020206

OTHER SOURCE(S): MARPAT 137:195554

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:657949 CAPLUS

DOCUMENT NUMBER: 137:195553

TITLE: Epothilone derivatives for the treatment of refractory tumors

INVENTOR(S): Lee, Francis Y. F.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066033	A1	20020829	WO 2002-US4247	20020206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1368030	A1	20031210	EP 2002-724940	20020206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300397	A	20031215	EE 2003-397	20020206
BR 2002007316	A	20040210	BR 2002-7316	20020206
JP 2004522771	T2	20040729	JP 2002-565591	20020206
US 2002165257	A1	20021107	US 2002-71988	20020208
US 6727276 <i>opp</i>	B2	20040427		
NO 2003003682	A	20030819	NO 2003-3682	20030819
PRIORITY APPLN. INFO.:			US 2001-269858P	P 20010220
			WO 2002-US4247	W 20020206

OTHER SOURCE(S): MARPAT 137:195553
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:601155 CAPLUS
DOCUMENT NUMBER: 137:163459
TITLE: Validation of the pharmacodynamics of BMS-247550, an
analogue of epothilone B, during a phase I clinical
study
AUTHOR(S): McDaid, Hayley M.; Mani, Sridhar; Shen, Heng-Jia;
Muggia, Franco; Sonnichsen, Daryl; Horwitz, Susan Band
CORPORATE SOURCE: Department of Molecular Pharmacology, Albert Einstein
College of Medicine, Bronx, NY, 10461, USA
SOURCE: Clinical Cancer Research (2002), 8(7), 2035-2043
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 24 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:576244 CAPLUS
DOCUMENT NUMBER: 137:149638
TITLE: Epothilones: a novel class of non-taxane
microtubule-stabilizing agents
AUTHOR(S): Altaha, Ramin; Fojo, Tito; Reed, Eddie; Abraham, Jame
CORPORATE SOURCE: Mary Babb Randolph Cancer Center, Robert C. Byrd
Health Sciences Center, West Virginia University,
Morgantown, WV, 26506, USA
SOURCE: Current Pharmaceutical Design (2002), 8(19), 1707-1712
CODEN: CPDEFP; ISSN: 1381-6128
PUBLISHER: Bentham Science Publishers
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 25 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:574930 CAPLUS
DOCUMENT NUMBER: 137:129900
TITLE: Methods of administering epothilone analogs for the
treatment of **cancer**
INVENTOR(S): Bandyopadhyay, Rebanta; Malloy, Timothy M.; Panaggio,
Andrea; Raghavan, Krishnaswamy Srinivas; Varia,
Sailesh Amilal
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058700	A1	20020801	WO 2002-US1813	20020122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EE 200300320	A	20031015	EE 2003-320	20020122

EP 1353668 A1 20031022 EP 2002-713446 20020122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2002169190 A1 20021114 US 2002-55653 20020123
US 6670384 X B2 20031230
NO 2003003341 A 20030904 NO 2003-3341 20030724
PRIORITY APPLN. INFO.: US 2001-264228P P 20010125
US 2001-290006P P 20010511
WO 2002-US1813 W 20020122
OTHER SOURCE(S): MARPAT 137:129900
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 26 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:574929 CAPLUS
DOCUMENT NUMBER: 137:145575
TITLE: Pharmaceutical forms of epothilones for oral
administration
INVENTOR(S): Bandyopadhyay, Rebanta; Malloy, Timothy M.; Panaggio,
Andrea; Raghavan, Krishnaswamy Srinivas; Varia,
Sailesh Amilal
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058699	A1	20020801	WO 2002-US1693	20020122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002177615	A1	20021128	US 2002-57390	20020125
US 6576651 X	B2	20030610		
PRIORITY APPLN. INFO.:			US 2001-264228P	P 20010125
			US 2001-290019P	P 20010511
OTHER SOURCE(S):		MARPAT 137:145575		
REFERENCE COUNT:		2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	

L13 ANSWER 27 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:368935 CAPLUS
DOCUMENT NUMBER: 136:385973
TITLE: Synthesis of epothilones, intermediates and analogs
for use in treatment of **cancers** with
multidrug resistant phenotype
INVENTOR(S): Danishefsky, Samuel J.; Stachel, Shawn J.; Lee, Chul
Bom; Chappell, Mark D.; Chou, Ting-chao; Wu, Zhicai
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 125 pp., Cont.-in-part of U.S.
Ser. No. 257,072.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

US 2002058286	A1	20020516	US 2001-797027	20010301
US 6204388	B1	20010320	US 1999-257072	19990224
PRIORITY APPLN. INFO.:			US 1999-257072	A2 19990224
			US 1996-32282P	P 19961203
			US 1997-33767P	P 19970114
			US 1997-47566P	P 19970522
			US 1997-47941P	P 19970529
			US 1997-55533P	P 19970813
			US 1997-986025	A2 19971203
			US 1998-75947P	P 19980225
			US 1998-92319P	P 19980709
			US 1998-97733P	P 19980824

OTHER SOURCE(S): MARPAT 136:385973

L13 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:335937 CAPLUS
 DOCUMENT NUMBER: 137:288617
 TITLE: Ectopic overexpression of second mitochondria-derived
 activator of caspases (Smac/DIABLO) or cotreatment
 with N-terminus of Smac/DIABLO peptide potentiates
 epothilone B derivative-(BMS 247550) and
 Apo-2L/TRAIL-induced apoptosis
 AUTHOR(S): Guo, Fei; Nimmanapalli, Ramadevi; Paranawithana,
 Shanthi; Wittman, Sylvie; Griffin, David; Bali, Purva;
 O'Bryan, Erica; Fumero, Carlos; Wang, Hong-Gang;
 Bhalla, Kapil
 CORPORATE SOURCE: Interdisciplinary Oncology Program, Moffitt Cancer
 Center and Research Institute, University of South
 Florida, Tampa, FL, 33612, USA
 SOURCE: Blood (2002), 99(9), 3419-3426
 CODEN: BLOOAW; ISSN: 0006-4971
 PUBLISHER: American Society of Hematology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 29 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:108252 CAPLUS
 DOCUMENT NUMBER: 136:363413
 TITLE: Epothilone B analogue (BMS-247550)-mediated
 cytotoxicity through induction of Bax conformational
 change in human breast **cancer** cells
 AUTHOR(S): Yamaguchi, Hirohito; Paranawithana, Shanthi R.; Lee,
 Michael W.; Huang, Ziwei; Bhalla, Kapil N.; Wang,
 Hong-Gang
 CORPORATE SOURCE: Drug Discovery Program, H. Lee Moffitt Cancer Center
 and Research Institute, Tampa, FL, 33612, USA
 SOURCE: Cancer Research (2002), 62(2), 466-471
 CODEN: CNREA8; ISSN: 0008-5472
 PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 30 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:730715 CAPLUS
 DOCUMENT NUMBER: 135:288636
 TITLE: Synergistic methods and compositions for treating
 cancer using two or more anticancer agents
 INVENTOR(S): Lee, Francis Y.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072721	A2	20011004	WO 2001-US9193	20010322
WO 2001072721	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1272193	A2	20030108	EP 2001-920653	20010322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003528864	T2	20030930	JP 2001-570634	20010322
US 2002002162	A1	20020103	US 2001-817456	20010326
US 6537988	B2	20030325		
NO 2002004610	A	20021125	NO 2002-4610	20020926
ZA 2002007766	A	20030120	ZA 2002-7766	20020926
PRIORITY APPLN. INFO.:			US 2000-192278P	P 20000327
			WO 2001-US9193	W 20010322

OTHER SOURCE(S): MARPAT 135:288636

L13 ANSWER 31 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:696814 CAPLUS
 DOCUMENT NUMBER: 136:65
 TITLE: Ovarian **cancer**
 AUTHOR(S): Seiden, Michael V.
 CORPORATE SOURCE: Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA
 SOURCE: Oncologist (2001), 6(4), 327-332
 CODEN: OCOLF6; ISSN: 1083-7159
 PUBLISHER: AlphaMed Press
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 32 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:661399 CAPLUS
 DOCUMENT NUMBER: 135:226826
 TITLE: Synthesis of epothilones, intermediates and analogs for use in treatment of **cancers** with multidrug resistant phenotype
 INVENTOR(S): Danishefsky, Samuel J.; Lee, Chul Bom; Chappell, Mark; Stachel, Shawn; Chou, Ting-chao
 PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA
 SOURCE: PCT Int. Appl., 234 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064650	A2	20010907	WO 2001-US6643	20010301
WO 2001064650	A3	20020510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

Not the same compound

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2002058817 A1 20020516 US 2001-796959 20010301
 EP 1259490 A2 20021127 EP 2001-916335 20010301
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004500388 T2 20040108 JP 2001-563492 20010301
 PRIORITY APPLN. INFO.: US 2000-185968P P 20000301
 US 2000-250447P P 20001130
 WO 2001-US6643 W 20010301
 OTHER SOURCE(S): CASREACT 135:226826; MARPAT 135:226826

L13 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:526491 CAPLUS
 DOCUMENT NUMBER: 135:327022
 TITLE: The synthesis, discovery, and development of a highly
 promising class of microtubule stabilization agents:
 curative effects of desoxyepothilones B and F against
 human **tumor** xenografts in nude mice
 AUTHOR(S): Chou, Ting-Chao; O'Connor, Owen A.; Tong, William P.;
 Guan, Yongbiao; Zhang, Zui-Guo; Stachel, Shawn J.;
 Lee, Chulbom; Danishefsky, Samuel J.
 CORPORATE SOURCE: Preclinical Pharmacology Core Facility, Memorial
 Sloan-Kettering Cancer Center, New York, NY, 10021,
 USA
 SOURCE: Proceedings of the National Academy of Sciences of the
 United States of America (2001), 98(14), 8113-8118
 CODEN: PNASA6; ISSN: 0027-8424
 PUBLISHER: National Academy of Sciences
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 34 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:433618 CAPLUS
 DOCUMENT NUMBER: 136:193764
 TITLE: BMS-247550: A novel epothilone analog with a mode of
 action similar to paclitaxel but possessing superior
 antitumor efficacy
 AUTHOR(S): Lee, Francis Y. F.; Borzilleri, Robert; Fairchild,
 Craig R.; Kim, Soong-Hoon; Long, Byron H.;
 Reventos-Suarez, Carmen; Vite, Gregory D.; Rose,
 William C.; Kramer, Robert A.
 CORPORATE SOURCE: Oncology Drug Discovery, Bristol-Myers Squibb
 Pharmaceutical Research Institute, Princeton, NJ,
 08543, USA
 SOURCE: Clinical Cancer Research (2001), 7(5), 1429-1437
 CODEN: CCREF4; ISSN: 1078-0432
 PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:334742 CAPLUS
 DOCUMENT NUMBER: 135:107175
 TITLE: On the Interactivity of Complex Synthesis and
Tumor Pharmacology in the Drug Discovery
 Process: Total Synthesis and Comparative in Vivo
 Evaluations of the 15-Aza Epothilones
 AUTHOR(S): Stachel, Shawn J.; Lee, Chul Bom; Spassova, Maria;
 Chappell, Mark D.; Bornmann, William G.; Danishefsky,
 Samuel J.; Chou, Ting-Chao; Guan, Yongbiao
 CORPORATE SOURCE: Laboratories for Bioorganic Chemistry Preclinical
 Pharmacology and the Preparative Synthesis Core

SOURCE: Facility, The Sloan-Kettering Institute for Cancer,
Research, New York, NY, 10021, USA
Journal of Organic Chemistry (2001), 66(12), 4369-4378
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:107175

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 36 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:608747 CAPLUS

DOCUMENT NUMBER: 133:193030

TITLE: Preparation of C-21 modified epothilones for use as
anticancer agents

INVENTOR(S): Hoefle, Gerhard; Glaser, Nicole; Leibold, Thomas;
Vite, Gregory; Kim, Soong-hoon

PATENT ASSIGNEE(S): Gesellschaft fuer Biotechnologische Forschung MbH
(Gbf), Germany; Bristol-Myers Squibb Co.

SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050423	A1	20000831	WO 2000-US4068	20000217
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19907588	A1	20000824	DE 1999-19907588	19990222
DE 19930111	A1	20010104	DE 1999-19930111	19990701
CA 2360452	AA	20000831	CA 2000-2360452	20000217
AU 2000032348	A5	20000914	AU 2000-32348	20000217
AU 771089	B2	20040311		
EP 1157023	A1	20011128	EP 2000-910219	20000217
EP 1157023	B1	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008379	A	20020924	BR 2000-8379	20000217
JP 2002537395	T2	20021105	JP 2000-601003	20000217
EE 200100437	A	20021216	EE 2001-437	20000217
AT 254615	E	20031215	AT 2000-910219	20000217
NO 2001004017	A	20011017	NO 2001-4017	20010817
BG 105830	A	20020329	BG 2001-105830	20010817
LV 12755	B	20020420	LV 2001-126	20010823
HK 1038923	A1	20040319	HK 2002-100498	20020122
PRIORITY APPLN. INFO.:			DE 1999-19907588	A 19990222
			DE 1999-19930111	A 19990701
			WO 2000-US4068	W 20000217

OTHER SOURCE(S): MARPAT 133:193030

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 37 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:521831 CAPLUS

DOCUMENT NUMBER: 133:237723

TITLE: Synthesis and biological evaluation of aza-epothilones

AUTHOR(S): Schinzer, Dieter; Altmann, Karl-Heinz; Stuhlmann,

CORPORATE SOURCE: Friedrich; Bauer, Armin; Wartmann, Markus
Chemisches Institut der Otto-von-Guericke-Universitat,
Magdeburg, 39106, Germany
SOURCE: ChemBioChem (2000), 1(1), 67-70
Published in: Angew. Chem., Int. Ed., 39(13)
CODEN: CBCHFX; ISSN: 1439-4227
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English

L13 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:691099 CAPLUS
DOCUMENT NUMBER: 131:310503
TITLE: synthesis and cytotoxicity of 2,3-olefinic epothilone
derivatives for use in treatment of **tumors**
or other hyperproliferative cellular disease
INVENTOR(S): Vite, Gregory D.; Borzilleri, Robert M.; Hofle,
Gerhard; Leibold, Thomas
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954330	A1	19991028	WO 1999-US8114	19990414
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6498257	B1	20021224	US 1999-280210	19990329
CA 2329413	AA	19991028	CA 1999-2329413	19990414
AU 9935590	A1	19991108	AU 1999-35590	19990414
AU 756544	B2	20030116		
EP 1073654	A1	20010207	EP 1999-917475	19990414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002512245	T2	20020423	JP 2000-544669	19990414
US 2003060623	A1	20030327	US 2002-242437	20020913
PRIORITY APPLN. INFO.:			US 1998-82562P	P 19980421
			US 1999-280210	A3 19990329
			WO 1999-US8114	W 19990414

OTHER SOURCE(S): MARPAT 131:310503
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 39 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:691091 CAPLUS
DOCUMENT NUMBER: 131:310502
TITLE: synthesis and cytotoxicity of 12,13-modified
epothilone derivatives for use in treatment of
tumors or other hyperproliferative cellular
disease
INVENTOR(S): Vite, Gregory D.; Kim, Soong-Hoon Kim; Hofle, Gerhard
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954319	A1	19991028	WO 1999-US7475	19990405
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG				
US 6380395	B1	20020430	US 1999-280192	19990329
US 6399638	B1	20020604	US 1999-280191	19990329
CA 2329181	AA	19991028	CA 1999-2329181	19990405
AU 9934716	A1	19991108	AU 1999-34716	19990405
AU 748526	B2	20020606		
BR 9909795	A	20001226	BR 1999-9795	19990405
TR 200003036	T2	20010122	TR 2000-200003036	19990405
EP 1073648	A1	20010207	EP 1999-916383	19990405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002512239	T2	20020423	JP 2000-544658	19990405
PRIORITY APPLN. INFO.:			US 1998-82564P	P 19980421
			WO 1999-US7475	W 19990405
OTHER SOURCE(S):		MARPAT 131:310502		
REFERENCE COUNT:		2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L13 ANSWER 40 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:64791 CAPLUS

DOCUMENT NUMBER: 130:139205

TITLE: syntheses of epothilone derivatives and intermediates for use in treatment of hyperproliferative cellular disease

INVENTOR(S): Vite, Gregory D.; Borzilleri, Robert M.; Kim, Soong-hoon; Johnson, James A.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902514	A2	19990121	WO 1998-US12550	19980616
WO 9902514	A3	20010510		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6605599	B1	20030812	US 1998-84542	19980526
AU 9879720	A1	19990208	AU 1998-79720	19980616
AU 731497	B2	20010329		
EP 1019389	A2	20000719	EP 1998-930300	19980616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9810555	A	20000815	BR 1998-10555	19980616
EE 200000013	A	20000815	EE 2000-200000013	19980616
TR 200000065	T2	20001121	TR 2000-200000065	19980616
NZ 501198	A	20010928	NZ 1998-501198	19980616
JP 2002512634	T2	20020423	JP 1999-508673	19980616
RU 2213741	C2	20031010	RU 2000-102893	19980616

TW 562802	B	20031121	TW 1998-87110722	19980702
ZA 9805938	A	20000110	ZA 1998-5938	19980706
MX 9911452	A	20000630	MX 1999-11452	19991209
LT 4743	B	20001227	LT 1999-153	19991223
NO 2000000076	A	20000107	NO 2000-76	20000107
LV 12569	B	20010420	LV 2000-17	20000202
US 2003220295	A1	20031127	US 2003-405886	20030403
PRIORITY APPLN. INFO.:			US 1997-51951P	P 19970708
			US 1997-67524P	P 19971204
			US 1998-84542	A1 19980526
			WO 1998-US12550	W 19980616

OTHER SOURCE(S): MARPAT 130:139205

=>
=> d ibib abs 33-35

L13 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:526491 CAPLUS

DOCUMENT NUMBER: 135:327022

TITLE: The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human **tumor** xenografts in nude mice

AUTHOR(S): Chou, Ting-Chao; O'Connor, Owen A.; Tong, William P.; Guan, Yongbiao; Zhang, Zui-Guo; Stachel, Shawn J.; Lee, Chulbom; Danishefsky, Samuel J.

CORPORATE SOURCE: Preclinical Pharmacology Core Facility, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2001), 98(14), 8113-8118
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have evaluated two synthetic epothilone analogs lacking the 12,13-epoxide functionality, 12,13-desoxyepothilone B (dEpoB), and 12,13-desoxyepothilone F (dEpoF). The concns. required for 50% growth inhibition (IC50) for a variety of anticancer agents were measured in CCRF-CEM/VBL1000 cells (2,048-fold resistance to vinblastine). By using dEpoB, dEpoF, aza-EpoB, and paclitaxel, the IC50 values were 0.029, 0.092, 2.99, and 5.17 μ M, resp. These values represent 4-, 33.5-, 1,423- and 3,133-fold resistance, resp., when compared with the corresponding IC50 in the parent [nonmultiple drug-resistant (MDR)] CCRF-CEM cells. We then produced MDR human lung carcinoma A549 cells by continuous exposure of the **tumor** cells to sublethal concns. of dEpoB (1.8 yr), vinblastine (1.2 yr), and paclitaxel (1.8 yr). This continued exposure led to the development of 2.1-, 4,848-, and 2,553-fold resistance to each drug, resp. The therapeutic effect of dEpoB and paclitaxel was also compared in vivo in a mouse model by using various **tumor** xenografts. DEpoB is much more effective in reducing **tumor** sizes in all MDR **tumors** tested. Anal. of dEpoF, an analog possessing greater aqueous solubility than dEpoB, showed curative effects similar to dEpoB against K562, CCRF-CEM, and MX-1 xenografts. These results indicate that dEpoB and dEpoF are efficacious antitumor agents with both a broad chemotherapeutic spectrum and wide safety margins.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 34 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:433618 CAPLUS

DOCUMENT NUMBER: 136:193764

TITLE: BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy

AUTHOR(S): Lee, Francis Y. F.; Borzilleri, Robert; Fairchild, Craig R.; Kim, Soong-Hoon; Long, Byron H.;

Reventos-Suarez, Carmen; Vite, Gregory D.; Rose, William C.; Kramer, Robert A.
CORPORATE SOURCE: Oncology Drug Discovery, Bristol-Myers Squibb
Pharmaceutical Research Institute, Princeton, NJ,
08543, USA
SOURCE: Clinical Cancer Research (2001), 7(5), 1429-1437
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB BMS-247550, a novel epothilone derivative, is being developed by Bristol-Myers Squibb Company (BMS) as an anticancer agent for the treatment of patients with malignant **tumors**. BMS-247550 is a semisynthetic analog of the natural product epothilone B and has a mode of action analogous to that of paclitaxel (i.e., microtubule stabilization). In vitro, it is twice as potent as paclitaxel in inducing tubulin polymerization. Like paclitaxel, BMS-247550 is a highly potent cytotoxic agent capable of killing **cancer** cells at low nanomolar concns. Importantly, BMS-247550 retains its antineoplastic activity against human **cancers** that are naturally insensitive to paclitaxel or that have developed resistance to paclitaxel, both in vitro and in vivo. **Tumors** for which BMS-247550 demonstrated significant antitumor activity encompass both paclitaxel-sensitive and -refractory categories, i.e., (a) paclitaxel-resistant: HCT116/VM46 colorectal (multidrug resistant), Pat-21 breast and Pat-7 ovarian carcinoma (clin. isolates; mechanisms of resistance not fully known), and A2780Tax ovarian carcinoma (tubulin mutation); (b) paclitaxel-insensitive: Pat-26 human pancreatic carcinoma (clin. isolate) and M5076 murine fibrosarcoma; and (c) paclitaxel sensitive: A2780 ovarian, LS174T, and HCT116 human colon carcinoma. In addition, BMS-247550 is p.o. efficacious against preclin. human **tumor** xenografts grown in immunocompromised mice or rats. Schedule optimization studies indicate that BMS-247550 is efficacious when administered frequently (every 2 days + 5) or intermittently (every 4 days + 3 or every 8 days + 2). These efficacy data demonstrate that BMS-247550 has the potential to surpass Taxol in both clin. efficacy and ease of use (i.e., less frequent treatment schedule and/or oral administration).
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:334742 CAPLUS
DOCUMENT NUMBER: 135:107175
TITLE: On the Interactivity of Complex Synthesis and
Tumor Pharmacology in the Drug Discovery
Process: Total Synthesis and Comparative in Vivo
Evaluations of the 15-Aza Epothilones
AUTHOR(S): Stachel, Shawn J.; Lee, Chul Bom; Spassova, Maria;
Chappell, Mark D.; Bornmann, William G.; Danishefsky,
Samuel J.; Chou, Ting-Chao; Guan, Yongbiao
CORPORATE SOURCE: Laboratories for Bioorganic Chemistry Preclinical
Pharmacology and the Preparative Synthesis Core
Facility, The Sloan-Kettering Institute for Cancer,
Research, New York, NY, 10021, USA
SOURCE: Journal of Organic Chemistry (2001), 66(12), 4369-4378
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:107175

AB The total syntheses of 12,13,15-desoxy-15(S)-aza-epothilone B (aza-dEpoB; dEpoB-lactam) and 12,13,15-desoxy-15(R)-aza-epothilone B (15-epi-aza-dEpoB; 15-epi-dEpoB-lactam) have been accomplished via a highly convergent strategy. We have also successfully oxidized 12,13,15-desoxy-15(S)-aza-epothilone B to aza-epothilone B (aza-EpoB; EpoB-lactam). Aza-epothilone B has been advanced to phase I clin. trials by the Bristol-Myers Squibb group. Our synthesis is efficient and was amenable to the production of significant quantities of these lactams. Using

our fully synthetically derived lactams, in vitro and in vivo studies were conducted in comparison with advanced clin. candidates, 12,13-desoxyepothilone B and 12,13-desoxyepothilone F, also derived by total synthesis.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT